Related Experiment Video
Updated: Jun 2, 2026

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model
Published on: July 29, 2012
Clinical and pathological study of asymptomatic HBsAg carriers in Chile
Insights
Chronic Hepatitis B carriers were studied, revealing a link between elevated alpha-fetoprotein and hepatocarcinoma development. Early detection in HBsAg carriers is crucial for monitoring liver health.
Area of Science:
- Hepatology
- Virology
- Clinical Medicine
Background:
- Hepatitis B virus (HBV) infection is a global health concern, leading to chronic liver disease.
- Chronic carriers of the Hepatitis B surface antigen (HBsAg) require careful monitoring for potential complications.
- Understanding the clinical and pathological spectrum of chronic HBsAg carriage is essential for patient management.
Purpose of the Study:
- To investigate the clinical, biochemical, and pathological features of chronic HBsAg carriers.
- To assess the correlation between liver function tests and liver histology in this cohort.
- To identify potential early markers for hepatocarcinoma development in chronic HBV carriers.
Main Methods:
- A cohort of 38 chronic HBsAg carriers was selected from a larger group of voluntary blood donors.
- Clinical evaluation, biochemical tests, and liver biopsy were performed.
- Alpha-fetoprotein levels and liver histology were analyzed for correlation with disease progression.
Main Results:
- Liver biopsy results varied, including normal histology, non-specific hepatitis, fatty changes, chronic persistent hepatitis, aggressive hepatitis, and cirrhosis.
- No strong correlation was found between liver function tests and liver histology.
- Two patients with elevated alpha-fetoprotein subsequently developed hepatocarcinoma within 14 months.
Conclusions:
- Elevated alpha-fetoprotein is a significant indicator for hepatocarcinoma in chronic HBsAg carriers.
- Regular monitoring of HBsAg carriers, particularly those with elevated alpha-fetoprotein, is vital for early hepatocarcinoma detection.
- Further research is needed to elucidate the precise mechanisms linking HBsAg, alpha-fetoprotein, and hepatocarcinogenesis.
Abstract:
A clinical, biochemical, and pathological study was performed in 38 chronic HBsAg carriers. The study group is a part of 393 carriers found among 117 705 voluntary blood donors at the National Blood Bank, Hospital del Salvador, Santiago, Chile. None of the 38 carriers had a past history of illicit drug abuse, hepatitis, or work involving a high risk of hepatitis B virus infection. Ten individuals had a normal liver biopsy, 17 reactive non-specific hepatitis, one fatty changes, four chr onic persistent hepatitis, one aggressive hepatitis, two post-necrotic cirrhosis, and three alcoholic cirrhosis. There was not a close correlation between liver function test and liver histology. The most significant laboratory finding was the postivity of alpha fetoprotein in two cases. During the follow-up the two alpha fetoprotein patients presented a hepatocarcinoma 12 and 14 months after admission to the study.
Related Concept Videos
Cytomegalovirus Disease
Hepatitis
Genital Herpes
American Trypanosomiasis
Amebiasis

